Mestastop Solutions Secures INR 4.5 Cr to Advance Metastasis Research in the Health Sector

This funding round was led by a group of 92 angel investors and received support from Malpani Ventures.

Bangalore-based Mestastop Solutions, a biotechnology startup, has successfully raised INR 4.5 Cr (approximately $500,000) in a Pre-Series A funding round.

This funding round was led by a group of 92 angel investors and received support from Malpani Ventures. Notably, in 2021, the company secured seed funding of INR 2 Cr with the backing of IIM Ahmedabad's CIIE and participation from IKP and several angel investors.

The funds raised will be directed towards generating proof of concept data related to small molecules targeting the first-in-class identified targets.

Additionally, they will support efforts in drug repurposing to delay metastasis by identifying potential clinical candidates. This will also involve the development of new animal models and clinical studies, as well as strategic business development activities.

Commenting on the same, Dr Arnab Roy Chowdhury, one of the co-founders, said, "Over the last three years, we have been involved in extensive R&D, which has created novel platforms. We are ready to leap forward and use these platforms for our discovery and diagnostics efforts."

Founded in 2018, Mestastop Solutions, cofounded by Arnab Roy Chowdhury and Debabani Roy Chowdhury, is dedicated to studying cancer metastasis.

Their approach combines wet-lab biology and predictive analytics to identify and distinguish unique characteristics of metastasis, with the ultimate goal of leveraging these findings to discover new drugs and improve patient treatments.

Alok, a representative from the group of 92 angel investors, highlighted the noble mission of Mestastop in the battle against cancer. He said, "Mestastop is on a noble mission to defeat cancer, a dreaded disease that takes millions of lives every year. 92 Angels, a group of investors whose specific goal is to support companies that make a better world, is privileged to be part of Mestastop's journey."

Talking about the same, Dr Anirudh Malpani from Malpani Ventures, said, "We are pleased to back Arnab, Debabani, and the team at Mestastop. The company's vision of developing novel platforms and predictive diagnostics to solve cancer metastasis resonates well with our thesis at Malpani Ventures to back purpose-driven tech-first founders in healthcare."

According to the World Cancer Report, cancer will cost the world approximately $25 trillion by the year 2050, and research and treatment expenditures on cancer will total $400 billion by 2030.

A significant portion of this expenditure, around $150-180 billion, is expected to be allocated to the global drug discovery market, marking a crucial area for Mestastop Solutions as they tackle the complex problem of cancer metastasis.

This approach could potentially address a long-standing issue that has hindered progress in cancer cure pharmacology for years, leading to diminished returns on research and development efforts.

This funding injection marks a vital step forward in the fight against cancer and offers hope for more effective treatments in the future.